Recommended Topic Related To:

Daptacel

"The Vaccines for Children (VFC) Program offers vaccines at no cost for eligible children through doctors enrolled in the program. Find out if your child qualifies. Vaccinating on time means healthier children, families and communities.

"...

Daptacel

Daptacel

Daptacel Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Daptacel [(diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (DTaP)] is an immunization used to help prevent the diseases of diphtheria, tetanus, and pertussis. Most children who are vaccinated with DTaP will be protected throughout childhood. This medication is available in generic form. Common side effects include mild fever; redness, pain, tenderness, or swelling where the shot was given; fussiness for 1-3 days after the shot; tiredness or poor appetite for 1-3 days after the shot; or vomiting for 1-3 days after the shot.

Daptacel vaccine is administered as a 5 dose series at 2, 4 and 6 months of age (at intervals of 6-8 weeks), at 15-20 months of age and at 4-6 years of age. Daptacel may interact with steroids, cancer chemotherapy or radiation, azathioprine, basiliximab, cyclosporine, etanercept, leflunomide, muromonab-CD3, mycophenolate mofetil, sirolimus, or tacrolimus. Tell your doctor all medications and supplements you use and all vaccines you recently received. This medication may be harmful to a fetus and should not be given to a woman who is pregnant. Consult your doctor before breastfeeding.

Our Daptacel (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Daptacel in Detail - Patient Information: Side Effects

Keep track of any and all side effects your child has after receiving this vaccine. When the child receives the next booster dose, you will need to tell the doctor if the first shot caused any side effects. Getting diphtheria, tetanus, or pertussis disease is much riskier than getting DTaP vaccine. However, like any medicine, this vaccine, can cause side effects. The risk of DTaP vaccine causing a serious side effect is extremely small.

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if the child has any of the following serious side effects:

  • loss of consciousness;
  • seizure (black-out or convulsions);
  • high fever, over 105 degrees; or
  • non-stop crying for 3 hours or more.

Other less serious side effects may be more likely to occur. Talk to your doctor if your child has:

  • mild fever;
  • redness, pain, tenderness, or swelling where the shot was given;
  • fussiness for 1-3 days after the shot;
  • tiredness or poor appetite for 1-3 days after the shot; or
  • vomiting for 1-3 days after the shot.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

To help reduce fever and pain, your doctor may recommend giving the child an aspirin-free pain reliever such as acetaminophen (Tylenol, Tempra, others) or ibuprofen (Motrin, Advil). This may be given at the time of the shot and over the next 24 hours. Your doctor will tell you the correct dose to use. Controlling fever is especially important if the child has a history of seizures.

Read the entire detailed patient monograph for Daptacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) »

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Daptacel FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Data from Clinical Studies

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to vaccine use and for approximating rates of those events.

A total of 17,577 doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine have been administered to infants and children in 8 clinical studies. In all, 4,998 children received 3 doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine, 1,725 of these children received 4 doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine, and 485 of these children received 5 doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine.

In a randomized, double-blinded pertussis vaccine efficacy trial, the Sweden I Efficacy Trial, conducted in Sweden during 1992-1995, the safety of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine was compared with DT and a whole-cell pertussis DTP vaccine. A standard diary card was kept for 14 days after each dose and follow-up telephone calls were made 1 and 14 days after each injection. Telephone calls were made monthly to monitor the occurrence of severe events and/or hospitalizations for the 2 months after the last injection. There were fewer of the solicited common local and systemic reactions following DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine than following the whole-cell pertussis DTP vaccine. As shown in Table 1, the 2,587 infants who received DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine at 2, 4 and 6 months of age had similar rates of reactions within 24 hours as recipients of DT and significantly lower rates than infants receiving whole-cell pertussis DTP.

Table 1: Percentage of Infants from Sweden I Efficacy Trial with Local or Systemic Reactions within 24 Hours Post-Dose 1, 2 and 3 of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine compared with DT and Whole-Cell Pertussis DTP Vaccines

EVENT Dose 1
(2 MONTHS)
Dose 2
(4 MONTHS)
Dose 3
(6 MONTHS)
DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed)
vaccine
N = 2,587
DT
N =2,574
DTP
N =2,102
DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed)
vaccine
N = 2,563
DT
N =2,555
DTP
N =2,040
DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed)
vaccine
N = 2,549
DT
N =2,538
DTP
N =2,001
Local
  Tenderness (Any) 8.0* 8.4 59.5 10.1* 10.3 60.2 10.8* 10.0 50.0
  Redness ≥ 2 cm 0.3* 0.3 6.0 1.0* 0.8 5.1 3.7* 2.4 6.4
  Swelling ≥ 2 cm 0.9* 0.7 10.6 1.6* 2.0 10.0 6.3* 3.9 10.5
Systemic
  Fever 7.8* 7.6 72.3 19.1* 18.4 74.3 23.6* 22.1 65.1
   ≥ 38°C (100.4°F) Fretfulness§ 32.3 33.0 82.1 39.6 39.8 85.4 35.9 37.7 73.0
  Anorexia 11.2* 10.3 39.2 9.1* 8.1 25.6 8.4* 7.7 17.5
  Drowsiness 32.7* 32.0 56.9 25.9* 25.6 50.6 18.9* 20.6 37.6
  Crying ≥ 1 hour 1.7* 1.6 11.8 2.5* 2.7 9.3 1.2* 1.0 3.3
  Vomiting 6.9* 6.3 9.5 5.2** 5.8 7.4 4.3 5.2 5.5
DT: Swedish National Biologics Laboratories DTP: Sanofi Pasteur Inc.
N = Number of evaluable subjects
* p < 0.001: DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine versus whole-cell pertussis DTP
p < 0.0001: DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine versus DT
Rectal temperature
§ Statistical comparisons were not made for this variable
** p < 0.003: DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine versus whole-cell pertussis DTP

The incidence of serious and less common selected systemic events in the Sweden I Efficacy Trial is summarized in Table 2.

Table 2: Selected Systemic Events: Rates Per 1,000 Doses after Vaccination at 2, 4 and 6 Months of Age in Sweden I Efficacy Trial

EVENT Dose 1
(2 MONTHS)
Dose 2
(4 MONTHS)
Dose 3
(6 MONTHS)
DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed)
vaccine
N = 2,587
DT
N =2,574
DTP
N =2,102
DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed)
vaccine
N = 2,565
DT
N =2,556
DTP
N =2,040
DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed)
vaccine
N = 2,551
DT
N =2,539
DTP
N =2,002
Rectal temperature ≥ 40°C (104°F) within 48 hours of vaccination 0.39 0.78 3.33 0 0.78 3.43 0.39 1.18 6.99
Hypotonic-hypo-responsive episode within 24 hours of vaccination 0 0 1.9 0 0 0.49 0.39 0 0
Persistent crying ≥ 3 hours within 24 hours of vaccination 1.16 0 8.09 0.39 0.39 1.96 0 0 1.0
Seizures within 72 hours of vaccination 0 0.39 0 0 0.39 0.49 0 0.39 0
N = Number of evaluable subjects

In the Sweden I Efficacy Trial, one case of whole limb swelling and generalized symptoms, with resolution within 24 hours, was observed following dose 2 of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine. No episodes of anaphylaxis or encephalopathy were observed. No seizures were reported within 3 days of vaccination with DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine. Over the entire study period, 6 seizures were reported in the DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine group, 9 in the DT group and 3 in the whole-cell pertussis DTP group, for overall rates of 2.3, 3.5 and 1.4 per 1,000 vaccinees, respectively. One case of infantile spasms was reported in the DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine group. There were no instances of invasive bacterial infection or death.

In a US study, children received 4 doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine at 2, 4, 6, and 15-17 months of age. A total of 1,454 children received DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine and were included in the safety analyses. Of these, 51.7% were female, 77.2% Caucasian, 6.3% Black, 6.5% Hispanic, 0.9% Asian and 9.1% other races. In a subsequent study, a non-random subset of 485 of these children received a fifth dose of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine at 4-6 years of age. The children included in the fifth dose study were representative of all children who received four doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine in the earlier study with regard to frequencies of solicited local and systemic adverse events following the fourth dose. At 2, 4, and 6 months of age, DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine was administered concomitantly with Haemophilus influenzae type b (Hib) conjugate vaccine (tetanus toxoid conjugate) (sanofi pasteur, SA), inactivated poliovirus vaccine (IPV) (sanofi pasteur, SA), and 7-valent pneumococcal conjugate vaccine (Wyeth Pharmaceuticals Inc.). Infants had received the first dose of hepatitis B vaccine at 0 months of age. At 2 and 6 months of age, hepatitis B vaccine (recombinant) (Merck & Co., Inc.) was also administered concomitantly with DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine. Based on random assignment, the fourth dose of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine was administered either alone; concomitantly with Hib conjugate (tetanus toxoid conjugate) vaccine; or concomitantly with Hib conjugate (tetanus toxoid conjugate) vaccine, 7-valent pneumococcal conjugate vaccine, measles, mumps, rubella (MMR) vaccine (Merck & Co., Inc.), and varicella vaccine (Merck & Co., Inc.). The fifth dose of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine was administered concomitantly with IPV and MMR vaccine.

In the US studies, the occurrence of solicited local and systemic adverse events listed in Table 3 was recorded daily by parents or guardians for Days 0-7 following vaccination. For Days 0 and 1 following the first three doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine, signs and symptoms of HHE also were solicited. Periodic telephone calls were made to inquire about adverse events. Serious adverse events were monitored during the two studies, through 6 months following the fourth and fifth doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine, respectively.

The incidence and severity of selected solicited local and systemic adverse events that occurred within 3 days following each dose of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine are shown in Table 3. The incidence of redness, tenderness and swelling at the DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) injection site increased with the fourth and fifth doses, with the highest rates reported after the fifth dose.

Table 3: Number (Percentage) of Children from US Studies with Selected Solicited Local and Systemic Adverse Events by Severity Occurring Between 0 to 3 Days after Each Dose of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) Vaccine

  Dose 1* Dose 2* Dose 3* Dose 4* Dose 5*
N = 1390-1406
%
N = 1346-1360
%
N = 1301-1312
%
N = 1118-1144
%
N = 473-481
%
Injection Site Reactions (DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine injection site)
Redness
   > 5 mm 6.2 7.1 9.6 17.3 35.8
  25 - 50 mm 0.6 0.5 1.9 6.3 10.4
   > 50 mm 0.4 0.1 0.0 3.1 15.8
Swelling
   > 5 mm 4.0 4.0 6.5 11.7 23.9
  25 - 50 mm 1.2 0.6 1.0 3.2 5.8
   > 50 mm 0.4 0.1 0.1 1.6 7.7
Tenderness
  Any 48.8 38.2 40.9 49.5 61.5
  Moderate 16.5 9.9 10.6 12.3 11.2
  Severe 4.1 2.3 1.7 2.2 1.7
Increase in Arm Circumference
   > 5 mm       30.1 38.3
  20 - 40 mm - - - 7.0 14.0
   > 40 mm       0.4 1.5
Interference with Normal Activity of the Arm§
  Any - - - - 20.4
  Moderate         5.6
  Severe         0.4
Systemic Reactions
Fever**
   ≥ 38.0°C 9.3 16.1 15.8 10.5 6.1
   > 38.5-39.5°C 1.5 3.9 4.8 2.7 2.1
   > 39.5°C 0.1 0.4 0.3 0.7 0.2
Decreased Activity/Lethargy††
  Any 51.1 37.4 33.2 25.3 21.0
  Moderate 23.0 14.4 12.1 8.2 5.8
  Severe 1.2 1.4 0.6 1.0 0.8
Inconsolable Crying‡‡
  Any 58.5 51.4 47.9 37.1 14.1
  Moderate 14.2 12.6 10.8 7.7 3.5
  Severe 2.2 3.4 1.4 1.5 0.4
Fussiness/Irritability§§
  Any 75.8 70.7 67.1 54.4 34.9
  Moderate 27.7 25.0 22.0 16.3 7.5
  Severe 5.6 5.5 4.3 3.9 0.4
* In one U.S. study, children received four doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine. A non-random subset of these children received a fifth dose of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine in a subsequent study.
Doses 1-4 - Moderate: subject cries when site is touched; Severe: subject cries when leg or arm is moved. Dose 5 - Moderate: interfered with activities, but did not require medical care or absenteeism; Severe: incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism.
The circumference of the DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine-injected arm at the level of the axilla was monitored following the fourth and fifth doses only. Increase in arm circumference was calculated by subtracting the baseline circumference pre-vaccination (Day 0) from the circumference post-vaccination
§ Moderate: decreased use of arm, but did not require medical care or absenteeism; Severe: incapacitating, refusal to move arm, may have/or required medical care or absenteeism.
** For Doses 1-3, 53.7% of temperatures were measured rectally, 45.1% were measured axillary, 1.0% were measured orally, and 0.1% were measured by an unspecified route. For Dose 4, 35.7% of temperatures were measured rectally, 62.3% were measured axillary, 1.5% were measured orally, and 0.5% were measured by an unspecified route. For Dose 5, 0.2% of temperatures were measured rectally, 11.3% were measured axillary, 88.4% were measured orally. Fever is based upon actual temperatures recorded with no adjustments to the measurement for route.
†† Dose 1-4 - Moderate: interferes with and limits daily activity, less interactive; Severe: disabling (not interested in usual daily activity, subject cannot be coaxed to interact with caregiver). Dose 5 - Moderate: interfered with activities, but did not require medical care or absenteeism; Severe: incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism.
‡‡ Doses 1-4 - Moderate: 1 to 3 hours inconsolable crying; Severe: > 3 hours inconsolable crying. Dose 5 - Moderate: interfered with activities, but did not require medical care or absenteeism; Severe: incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism.
§§ Doses 1-4: Moderate: Irritability for 1 to 3 hours; Severe: irritability for > 3 hours. Dose 5: Moderate: interfered with activities, but did not require medical care or absenteeism; Severe: incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism.

In the US study in which children received 4 doses of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine, of 1,454 subjects who received DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine, 5 (0.3%) subjects experienced a seizure within 60 days following any dose of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine. One seizure occurred within 7 days post-vaccination: an infant who experienced an afebrile seizure with apnea on the day of the first vaccination. Three other cases of seizures occurred between 8 and 30 days post-vaccination. Of the seizures that occurred within 60 days post-vaccination, 3 were associated with fever. In this study, there were no reported cases of HHE following DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine. There was one death due to aspiration 222 days post-vaccination in a subject with ependymoma. Within 30 days following any dose of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine, 57 (3.9%) subjects reported at least one serious adverse event. During this period, the most frequently reported serious adverse event was bronchiolitis, reported in 28 (1.9%) subjects. Other serious adverse events that occurred within 30 days following DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine include three cases of pneumonia, two cases of meningitis and one case each of sepsis, pertussis (post-dose 1), irritability and unresponsiveness.

In the 5th dose study of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine in the US, within 30 days following the 5th dose consecutive dose of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine, 1 (0.2%) subject reported 2 serious adverse events (bronchopasm and hypoxia).

In another study (Sweden II Efficacy Trial), 3 DTaP vaccines and a whole-cell pertussis DTP vaccine, none of which are licensed in the US, were evaluated to assess relative safety and efficacy. This study included HCPDT, a vaccine made of the same components as DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine but containing twice the amount of detoxified PT and four times the amount of FHA (20 µg detoxified PT and 20 µg FHA). HHE was observed following 29 (0.047%) of 61,220 doses of HCPDT; 16 (0.026%) of 61,219 doses of an acellular pertussis vaccine made by another manufacturer; and 34 (0.056%) of 60,792 doses of a whole-cell pertussis DTP vaccine. There were 4 additional cases of HHE in other studies using HCPDT vaccine for an overall rate of 33 (0.047%) in 69,525 doses.

Data from Post-Marketing Experience

The following adverse events have been spontaneously reported during the post-marketing use of DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine in the US and other countries. Because these events are reported voluntarily from a population of uncertain size, it may not be possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.

The following adverse events were included based on severity, frequency of reporting or the strength of causal association to DAPTACEL (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) vaccine.

  • Cardiac disorders

Cyanosis

  • Gastro-intestinal disorders

Nausea, diarrhea

  • General disorders and administration site conditions:

Local reactions: injection site pain, injection site rash, injection site nodule, injection site mass, extensive swelling of injected limb (including swelling that involves adjacent joints).

  • Infections and infestations

Injection site cellulitis, cellulitis, injection site abscess

  • Immune system disorders

Hypersensitivity, allergic reaction, anaphylactic reaction (edema, face edema, swelling face, pruritus, rash generalized) and other types of rash (erythematous, macular, maculo-papular)

  • Nervous system disorders

Convulsions: febrile convulsion, grand mal convulsion, partial seizures. HHE, hypotonia, somnolence

  • Psychiatric disorders Screaming

Read the entire FDA prescribing information for Daptacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.

Related Drugs
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations